2026年2月17日,第一天生物制药公司CFO出售70.3K美元的股份,将他的股份减少了近2%。 
On Feb. 17, 2026, Day One Biopharmaceuticals' CFO sold $70.3K in shares, reducing his stake by nearly 2%.
2026年2月17日, Charles York II, CFO of Day One生物制药公司(DAWN)出售6 065股,每股11.60美元,股份减少1.91%至312 025股,价值约362万美元。 On February 17, 2026, Charles York II, CFO of Day One Biopharmaceuticals (DAWN), sold 6,065 shares at $11.60 each, reducing his stake by 1.91% to 312,025 shares, valued at about $3.62 million. 该交易在SEC档案中披露。 The transaction was disclosed in an SEC filing. 该公司的股票在2月18日以11.56美元关闭,减少了0.32美元,数额低于平均水平。 The company’s stock closed at $11.56 on February 18, down $0.32, with below-average volume. 临床肿瘤学公司 " 第一天生物制药公司 " 的市场上限为11.9亿美元,负P/E比率为7.61。 Day One Biopharmaceuticals, a clinical-stage oncology firm, has a market cap of $1.19 billion and a negative P/E ratio of -7.61. 分析师有好坏参半的共识,平均为25.71美元的目标价格的“机动购买”。 Analysts have a mixed consensus, averaging “Moderate Buy” with a $25.71 target price.
